LGBTQ Nation on MSN
Groundbreaking HIV-prevention med won’t harm trans people’s hormone therapy
Compounding that statistic, prior studies indicate some trans people at high risk for HIV transmission are hesitant to take ...
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Zimbabwe is preparing to place at least 46 500 people on a long-acting HIV prevention drug early next year marking the ...
Long Island Press on MSN
The breakthrough drug transforming HIV prevention: FDA-approved lenacapavir protects with twice-yearly injections
The U.S. Food and Drug Administration (FDA) recently approved a groundbreaking new option for preventing HIV, the virus that ...
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...
Gilead's ARTISTRY-2 trial shows BIC/LEN is non-inferior to Biktarvy in virologically suppressed adults with HIV, with no new safety signals. ARTISTRY-2's design involved a randomized, double-blind ...
The Trump administration's funding cuts to PEPFAR and USAID disrupted global HIV treatment and prevention, threatening progress made over decades. Lenacapavir's FDA approval as a long-acting ...
Bi-monthly HIV injection could transform care for breastfeeding mothers, improving suppression and cutting transmission.
Zimbabwe to administer the long‑acting HIV prevention drug Lenacapavir to at least 46,500 people early next year, a senior ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback